Weave Communications Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, ratification of the accounting firm, and board updates. Both nominated directors were elected and the auditor's appointment was ratified. No shareholder questions were raised, and risks were referenced in recent SEC filings.
-
Q1 2026 saw 17.4% revenue growth, record new locations, and expanding margins, with strong adoption of AI-powered products and payments solutions. Full-year guidance was raised, and the company is positioned for continued growth and margin improvement.
-
AI-powered engagement and payments solutions are driving strong growth, with revenue up 17% and free cash flow up 24%. New AI products and expanded verticals are accelerating upsell and market penetration, while operational leverage and profitability continue to improve.
Fiscal Year 2025
-
Delivered 17% revenue growth and record gross margin in 2025, with strong free cash flow and expanding AI-powered solutions. Specialty medical and payments segments led growth, while new partnerships and product launches position the company for continued momentum in 2026.
-
Q3 saw 17.1% revenue growth, record gross margin, and strong free cash flow, driven by AI-powered automation and expanding specialty medical and payments segments. Full-year guidance was raised, with continued investment in integrations and product innovation.
-
AI integration is driving workflow automation, payment modernization, and profitability for SMB healthcare practices, with significant growth potential in underpenetrated verticals and new markets. Financial targets include ARR growth to $500 million and expanded high-margin payment solutions.
-
Q2 2025 revenue grew 15.6% year-over-year to $58.5M, with record sales and strong free cash flow. Gross margin improved, TrueLark was acquired and integrated, and specialty medical became the second largest vertical. Full-year guidance was raised, with profitability set to improve.
-
The meeting covered director elections, auditor ratification, and corporate governance procedures. All proposals passed, with no questions from shareholders. Forward-looking statements were noted as subject to risks and uncertainties.
-
Q1 2025 revenue grew 18.3% year-over-year to $55.8M, with gross margin up 170 bps to 72.1%. Announced $35M acquisition of TrueLark to expand AI automation and addressable market, raising full-year revenue guidance to $236.8–239.8M.
Fiscal Year 2024
-
Revenue grew 20% in 2024 with record profitability and free cash flow, driven by strong specialty medical and payments growth. 2025 guidance anticipates continued double-digit growth, ongoing investments in payments, AI, and partnerships, and a CFO transition.
-
Q3 saw over 20% revenue growth, first-ever positive non-GAAP operating income, and gross margin expansion to 72.5%. Specialty medical led segment growth, while new platform launches and strategic partnerships fueled momentum. Raised full-year guidance and expect continued profitability.
-
Q2 revenue grew 21.4% year-over-year to $50.6 million, with gross margin up to 71.9% and first-ever positive Adjusted EBITDA. Specialty medical led growth, partnerships expanded, and full-year guidance was raised, reflecting strong execution and resilient demand.